New pharma rules risk 'sabotaging' life sciences in Europe, says the industry | Science
The European Commission has unveiled long-awaited proposals to reform EU’s pharmaceutical legislation to enable better access to drugs and promote innovation, but industry doesn’t like the look of it. The first revision of the legislation in over 20 years aims to make medicines more available, accessible and affordable, while boosting innovation and industrial competitiveness, by simplifying regulations and speeding up the scientific evaluation and authorisation of new drugs.